Zai Lab (ZLAB) and Pfizer (PFE) said Thursday they are collaborating on the commercialization of XACDURO in mainland China.
The companies said Pfizer's affiliates will exclusively handle commercialization activities for the drug approved for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex.
The partnership for the imported product runs through November 2028, with options for early termination or extension.
Price: 25.80, Change: -0.43, Percent Change: -1.64
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments